Prosidyan Launches FIBERGRAFT BG MATRIX for Posterolateral Spinal Fusion

By Julie A. Vetalice

Prosidyan announced FDA 510(k) clearance and commercial launch of FIBERGRAFT BG Matrix, a bone graft substitute for posterolateral spinal fusion.

This represents the third bioactive glass fiber-based product in the FIBERGRAFT line. Other formats include putty and morsels.

FIBERGRAFT products have been implanted in >9,000 recipients across the U.S. This is an increase from >7,000 at the end of 2Q17.

Source: Prosidyan

Product Labels: Synthetic Bone Graft

Tags: 510(k) Clearance, Regulatory